[Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].

doi:10.3779/j.issn.1009-3419.2022.101.54

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

[Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Dec 2022

Chen Ran, Jiang Chang, Tang Jun, Ma Li, Zhang Shucai

Abstract excerpt

Mesenchymal-epithelial transition factor (MET) has long been considered as the most crucial and promising driver gene in the occurrence and development of non-small cell lung cancer (NSCLC), except for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ROS oncogene 1 receptor tyrosine kinase (ROS1). In recent years, therapeutic drugs targeting MET have been continuously developed and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm
Share to ErbB Receptors
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 36617474
DOI: 10.3779/j.issn.1009-3419.2022.101.54
PMCID: PMC9845091

Provenance

PubMed metadata and Literature Corpus relationships.